Kemadrin (Procyclidine Hydrochloride)

Procyclidine is used to treat movement disorders that arise from excessive cholinergic activity in the central nervous system.

• Parkinsonian tremor and rigidity: reduces tremor amplitude and muscle stiffness in patients with Parkinson’s disease.
• Drug‑induced dystonia: alleviates sustained muscle contractions caused by antipsychotic medications.
• Akathisia: diminishes restlessness and urge to move associated with dopamine‑blocking agents.
• Antipsychotic‑related tremor: lessens fine tremor that develops during neuroleptic therapy.

• Procyclidine acts as a competitive antagonist at muscarinic acetylcholine receptors, particularly the M1 subtype, in the central nervous system. By blocking these receptors, it reduces cholinergic neurotransmission that opposes dopaminergic pathways, thereby restoring a more balanced motor control. This antagonism diminishes the over‑activity that contributes to tremor, rigidity, and other extrapyramidal manifestations and improves overall motor function.

Procyclidine may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Dry mouth: reduced salivation leading to thirst and difficulty swallowing.
• Blurred vision: difficulty focusing at near distances.
• Constipation: slowed gastrointestinal motility.
• Urinary retention: difficulty initiating urination.
• Nausea: upset stomach and possible vomiting.
• Drowsiness: increased sleepiness or fatigue.

Serious or Rare Side Effects

• Confusion or delirium: acute changes in mental status.
• Tachycardia: rapid heart rate that may require monitoring.
• Severe allergic reaction: rash, swelling, or anaphylaxis.
• Hallucinations: visual or auditory disturbances.

When prescribing Procyclidine, clinicians should consider several safety precautions to minimize risk.

• Assess renal and hepatic function: adjust use in patients with severe impairment.
• Monitor for anticholinergic burden: avoid concurrent use with other strong anticholinergics.
• Evaluate cognitive status: patients with dementia may experience worsening confusion.
• Review cardiac history: tachycardia or arrhythmias may be exacerbated.
• Store at ambient temperature: keep below 25 °C in the original container, protected from moisture.

Procyclidine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Other anticholinergic agents: additive anticholinergic effects may cause severe dryness, urinary retention, or cognitive impairment.
• QT‑prolonging drugs: combined use can increase risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely)

• Dopaminergic medications: may reduce therapeutic benefit of Procyclidine.
• CNS depressants (e.g., benzodiazepines): enhanced sedation and dizziness.
• Antihistamines with anticholinergic activity: increased likelihood of dry mouth and blurred vision.